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Interactions between phenytoin and the fluoropyrimidine derivatives, 5 fluorouracil (5FU) and capecitabine, are not commonly
documented or widely recognised. As more people with significant medical comorbidities are now being considered for
chemotherapy, it is increasingly likely that people receiving phenytoin will be prescribed treatment with fluoropyrimidines. We
present two cases of clinical phenytoin toxicity occurring after starting treatment with 5-fluorouracil/folinic acid (5FU/FA) and a third
who developed clinical phenytoin toxicity after starting capecitabine (an orally administered prodrug of fluorouracil).
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CASE I
A 65-year-old Asian man, with a history of more than 10 years of
idiopathic generalised tonic clonic epilepsy, had been treated with
a stable dose of phenytoin (300mg daily) and phenobarbitone
(90mg daily). He was diagnosed with Dukes’ B adenocarcinoma of
the colon in 1999. He had recurrence of the disease in 2002 with an
intra-abdominal mass, para-aortic lymphadenopathy and pulmon-
ary metastases. He was started on palliative 5FU/FA at doses of 370
and 20mgm
 2 weekly. His past medical history was unremarkable
and his other medications were morphine, lactulose, coloxyl and
senna, multivitamins, and loratadine. His liver enzymes were
normal.
Seven weeks after starting chemotherapy he was admitted
with a 10-day history of progressive confusion, drowsiness,
generalised weakness, and fatigue preventing him from walking.
On examination he was drowsy, dysarthric, had bilateral gaze
evoked nystagmus and marked limb ataxia. He was unable to stand
unsupported. The serum phenytoin level was 162mmoll
 1
(therapeutic level 40–80mmoll
 1). His phenobarbitone level was
89mmoll
 1 (therapeutic level 65–170mmoll
 1).
The phenytoin was withheld for 5 days until his serum level was
less than 80mmoll
 1. His symptoms and signs resolved with the
falling serum phenytoin level. He was restarted on a reduced dose
of phenytoin (230mg daily) when his serum level was 67mmoll
 1.
On this dose, his serum phenytoin level initially increased to
75mmoll
 1 before dropping to 22mmoll
 1 5 weeks after stopping
chemotherapy. The chemotherapy was stopped after two cycles
due to progression of the disease.
CASE 2
The second case is of a 60-year-old man with a history of post-
traumatic generalised tonic clonic epilepsy caused by a head injury
in 1988. He was treated with phenytoin 430mg daily (200mg mane,
230mg nocte) with stable phenytoin serum levels (75mmoll
 1 on
17.11.2000) and no symptoms of phenytoin toxicity since that
time. He was on no other medications.
He was diagnosed with Dukes’ C adenocarcinoma of the
transverse colon and was started on adjuvant 5 FU/FA with the
same protocol as patient one.
At 4 weeks after starting chemotherapy, he presented with a
6-day history of progressive light-headedness and inability to
stand unsupported. On examination he had severe gait ataxia and
was unable to walk. His mental state and other neurological signs
were not documented. His phenytoin level was 213mmoll
 1. His
phenytoin was withheld for 7 days, until his level had come down
to 42mmoll
 1 when he was restarted on a reduced dose (300mg
daily). At this dose of phenytoin his serum level rose from 42 to
118mmoll
 1. His dose of phenytoin was further reduced and
he was discharged on 100mg phenytoin daily with ongoing
chemotherapy. Since discharge, he has had a seizure associated
with a subtherapeutic serum phenytoin level of 24mmoll
 1 and has
had his phenytoin dose increased to 200mgday
 1.
CASE 3
The last case is of a 45-year-old woman with a greater than 10-year
history of poorly controlled generalised tonic clonic epilepsy
requiring three anticonvulsants: phenytoin 400mg daily (200mg
twice a day); clobazam 10mg nocte; and sodium valproate 1gm
twice daily. Serum phenytoin levels fluctuated at this dose and the
last phenytoin level, 18 months before admission, was
141mmoll
 1. There are no levels available between then and when
she was admitted. Her other medications were ranitidine,
morphine, paracetamol, and fluticasone propionate.
She developed breast cancer in 2001 and underwent adjuvant
treatment with intravenous cyclophosphamide, methotrexate, and
5 FU (CMF) chemotherapy without clinical evidence of phenytoin
toxicity. Her cancer progressed and she commenced on palliative
chemotherapy (single-agent doxorubicin, followed by docetaxel, Received 8 April 2003; accepted 15 May 2003
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land finally twice daily capecitabine, completing two cycles). The
protocol used for CMF was: cyclophosphamide 100mgm
 2 day 1–
14, methotrexate 40mgm
 2 days 1 and 8, 5 FU 600mgm
 2 days 1
and 8 in a 4 weekly cycle and capecitabine was prescribed at a dose
of 1500mg twice daily for 14 days, repeating 3 weekly.
The first cycle of capecitabine was one-third (500mg twice a
day) her prescribed dose due to patient misunderstanding, but her
second dose was at the intended dose (1500mg twice a day).
Nearly 6 weeks after starting this therapy (just over 2 weeks after
the full therapeutic dose), she was admitted 2-day history of an
unsteady gait, recurrent falls, weakness, poor balance, and light-
headedness. On examination she had dysarthria, poor balance, and
limb ataxia. Her serum phenytoin level was 161mmoll
 1 (ther-
apeutic level 40–80mmoll
 1). Her phenytoin was withheld for 5
days until her serum phenytoin level was under 80mmoll
 1 and
the dose was reduced to 300mg daily. Her serum phenytoin level
increased on this reduced dose (level¼104mmoll
 1) and she
became light-headed again. She was finally discharged on 260mg
of phenytoin daily. After 2 months, her serum phenytoin level fell
to 18mmoll
 1 while remaining at this dose. Her capecitabine was
stopped after two cycles due to progressive disease.
DISCUSSION
Our three cases add to the small volume of literature suggesting
that there is a genuine interaction between 5FU and phenytoin.
This hypothesis is supported by the difficulty in maintaining a
nontoxic serum phenytoin level in our patients, despite reductions
in the daily dose of phenytoin during treatment. Further support
for the interaction between these medications was the fall in
phenytoin levels once the chemotherapy was discontinued, which
required ongoing phenytoin dose adjustments. This observation
provides further evidence of a drug interaction, which resolves
after treatment ends.
There are two case reports in the literature about interactions
between phenytoin and 5FU resulting in phenytoin toxicity and
one case report of two breast cancer patients who developed
phenytoin toxicity after capecitabine (Schaller, 2000; Gilbar and
Brodribb, 2001; Rosemergy and Findlay, 2002).
In accordance with these earlier reports, it seems unlikely that
the toxicity in our first two patients can be attributed to alterations
in phenytoin binding, absorption, sampling times for drug levels,
or changes in compliance. The first two patients had been on a
stable dose of phenytoin for more than 10 years without evidence
of phenytoin toxicity. Neither patient had significant abnormalities
in their liver enzymes or serum albumin to explain altered
phenytoin binding or clearance. In the third patient, the relation-
ship between her chemotherapy and serum phenytoin level is not
as definite as there are many other potential factors that could have
attributed to her elevated phenytoin level; in particular, her past
history of elevated phenytoin levels, long-standing cognitive
impairment, and hypoalbuminaemia. The observation that her
serum phenytoin level remained unstable despite a reduced dose in
hospital and supervised dispensing, suggests that capecitabine had
indeed altered the metabolism of phenytoin rather than it being
secondary to difficulties with compliance.
Phenytoin is metabolised in the liver, mainly by the CYP2C9
isoenzyme. A small amount is metabolised by the CYP2C19 isotype
(Ninomiya et al, 2000; Brandolese et al, 2001). Fluorouracil may
competitively inhibit the clearance of phenytoin by the CYP2C9
isoenzyme or alternatively, it may reduce its synthesis (Levy, 1995,
Gilbar and Brodribb, 2001), thereby explaining a delay in the
occurrence of toxicity.
Increased phenytoin plasma concentrations have been reported
during concomitant use of capecitabine, but formal interaction
studies have not been carried out. The mechanism of interaction is
thought to be at the level of the CYP2C9 isoenzyme system (Roche
Xeloda (capecitabine) data sheet), in accordance with its role as a
prodrug for 5 FU (van Cutsem and Peeters, 1999; Ratain 2002;
Wagstaff et al, 2003).
CONCLUSION
The risk of phenytoin toxicity with concurrent 5 FU administration
appears real. The combined evidence of these and previous cases
suggest that further investigations into how these medications
interact at the cytochrome isoenzyme level are warranted. In the
meantime, it is prudent to monitor for clinical manifestations of
phenytoin toxicity and perform more frequent phenytoin levels in
all patients receiving phenytoin and either 5 FU or capecitabine.
Monitoring should continue after the chemotherapy has finished
to ensure that the phenytoin level is sufficient to prevent seizures.
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